drugset / Trial / NCT03337815

A Specification Clinical Application Research of Tripterygium Wilfordii Treating Rheumatoid Arthritis

NCT03337815

RandomizedParallel-groupDouble-blindTreatment

Summary

Rheumatoid Arthritis (RA) is an autoimmune disease that results in a chronic inflammatory disorder that may affect many synovial joints, and may cause serious disability. It has been confirmed that Tripterygium Wilfordii has effects of anti-inflammatory, immunosuppressive and cartilage protection. This is a multicenter ,double Blind, randomized study to evaluated the efficacy and safety of Tripterygium Wilfordii in treating of patients with rheumatoid arthritis (RA) and establish a prediction model for Tripterygium Wilfordii response of rheumatoid arthritis (RA).

Timeline

Start
2017-10-28
Primary completion
2019-03-31
Completion
2019-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methotrexate Small molecule 10 mg Oral
Comparator Methotrexate Small molecule 15 mg Oral
Subject Tripterygium wilfordii Hook F Traditional medicine (herbal / TCM) 20 mg Oral

Indications